September 27, 2019 - Advicenne Publishes its 2019 Half-Year Financial Report

September 24, 2019 - Advicenne Presents 2019 Half-Year Financial Report and Confirms Financial Outlook

September 20, 2019 - Advicenne to present eight posters on the positive results of ADV7103 in the treatment of rare nephrological diseases at major international conferences

September 4, 2019 - Advicenne secures production of ADV7103 through long-term manufacturing supply agreement with Elaiapharm Lundbeck

September 3, 2019 - Advicenne to attend the J.P. Morgan Pan European Small / Mid Cap Conference in London

August 29, 2019 - Advicenne Announces First Patient Enrolled in US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 in distal Renal Tubular Acidosis (dRTA)

July 26, 2019 - Advicenne to Present at the Solebury Trout European Biotech Investor Day in NYC

July 18, 2019 - Financial Visibility and Accelerated Development

June 13, 2019 - Advicenne confirms prevalence of distal renal tubular acidosis (dRTA) and cystinuria at ISPOR conference

June 12, 2019 - Advicenne announces the successful listing of its shares on the regulated market of Euronext Brussels

May 23, 2019 - Advicenne annonce son intention de cotation sur le marché réglementé d’Euronext Bruxelles

May 23, 2019 - Advicenne announces its intention to list on the regulated market of Euronext Brussels

May 7, 2019 - Advicenne annonce la tenue de son Assemblée générale mixte le 24 mai 2019

April 30, 2019 - Advicenne Publishes its 2018 Annual Financial Report

April 30, 2019 - Advicenne annonce la mise à disposition de son rapport financier annuel 2018

April 9, 2019 - Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris

March 21, 2019 - Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

March 21, 2019 - Advicenne présente ses résultats financiers annuels au 31 décembre 2018 et confirme ses perspectives pour 2019

March 12, 2019 - Advicenne dépose une demande d’autorisation de mise sur le marché en Europe pour ADV7103 dans l’Acidose Tubulaire Rénale distale (ATRd)

March 12, 2019 - Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)

January 17, 2019 - Bilan semestriel du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont

January 7, 2019 - Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium

January 7, 2019 - Advicenne obtient l’autorisation de l’agence de santé belge d’initier l’étude pivot de phase II/III CORAL avec ADV7103 dans la cystinurie

December 21, 2018 - Advicenne Publishes its Financial Calendar for 2019

October 26, 2018 - Advicenne Wins Prestigious Prix Galien – Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes

October 15, 2018 - Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

October 4, 2018 - Advicenne to present additional data on ADV7103 at the European Society for Paediatric Nephrology during its 51st Annual Meeting

September 25, 2018 - Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

September 20, 2018 - Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018

September 12, 2018 - Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

September 11, 2018 - Advicenne to host a conference call on September 12, 2018 at 6 pm to comment its recent development

September 5, 2018 - Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

July 2, 2018 - Advicenne confirms ADV7103’ safety and efficacy after 24 months in the Phase III Extension Study

May 31, 2018 - Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

May 15, 2018 - Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

May 4, 2018 - Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria

April 30, 2018 - Advicenne publishes its annual financial report

April 10, 2018 - Advicenne 2017 Financial Results and Operational Perspectives for 2018

April 5, 2018 - Advicenne to Report Full Year 2017 Results and Business Update on April 10, 2018 and Host Conference Call at 7:15 PM CEST

February 12, 2018 - Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017

January 24, 2018 - Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs

January 5, 2018 - Partial exercise of over – allotment option

Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

14 + 8 =

© 2019 Advicenne